Infliximab MRI relaxation time in solution
DOI:
https://doi.org/10.15584/ejcem.2019.1.4Keywords:
infliximab, magnetic resonance imaging, relaxation timeAbstract
Introduction. The use of Quantitative Magnetic Resonance Imaging to drug monitoring in vitro or in vivo can provides a powerful means to map the effects of drugs on tissue activity.
Aim. The purpose of this study was to measure relaxation time of antibody phantom. For this purpose, infliximab sample was used.
Material and methods. The selected methods to detect relaxation time of antibody was Magnetic Resonance Imaging technique. We detected spin-lattice (T1) relaxation time and discuss differences where compare to water.
Results. The measurements of spin-lattice (T1) relaxation time showed significant differences. The results obtained in phantom indicate that we can use this result for measurements of relaxation time in vitro.
Conclusion. Infliximab is approved for severe cases of rheumatoid arthritis, together with methotrexate, for pronounced psoriasis and psoriasis-arthritis, ankylosing spondylitis as well as for chronic inflammatory bowel disease. We conclude, that Quantitative Magnetic Resonance Imaging can be used to monitor drug effects.
Downloads
References
Beals C, Baumgartner R, Peterfy C, et al. Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring. PLoS One. 2017;12(12):e0187397.
Thomassin L, Armengol-Debeir L, Charpentier C, et al. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease. World J Gastroenterol. 2017;23(23):4285-4292.
Dillman JR, Smith EA, Sanchez R, Adler J, Fazeli S, Zhang B, Davenport MS. DWI in Pediatric Small-Bowel Crohn Disease: Are Apparent Diffusion Coefficients Surrogates for Disease Activity in Patients Receiving Infliximab Therapy? AJR Am J Roentgenol. 2016;207(5):1002-1008.
Naganuma M, Okuda S, Hisamatsu T, et al. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment. Abdom Radiol (NY). 2017;42(1):141-151.
Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L. BMC Med Imaging, 2016;16(1):37.
Dillman JR, Carlos RC, Smith EA, et al. Relationship of Bowel MR Imaging to Health-related Quality of Life Measures in Newly Diagnosed Pediatric Small Bowel Crohn Disease. Radiology. 2016;280(2):568-75.
Buisson A, Hordonneau C, Goutte M, et al. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease. Dig Liver Dis, 2016;48(3):260-6.
Bhatnagar G, Dikaios N, Prezzi D, Vega R, Halligan S, Taylor SA. Changes in dynamic contrast-enhanced pharmacokinetic and diffusion-weighted imaging parameters reflect response to anti-TNF therapy in Crohn's disease. Br J Radiol. 2015;88(1055):20150547.
Neurath MF. Molecular Endoscopy and in vivo Imaging in Inflammatory Bowel Diseases. Dig Dis. 2015;33(1):32-36.
Stoll ML, Vaid YN, Guleria S, Beukelman T, Waite PD, Cron RQ. Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis. J Rheumatol. 2015;42(11):2155-9.
Hirota T, Suzuki T, Ogishima H, et al. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept. Mod Rheumatol. 2016;26(1):29-35.
Gibson DJ, Murphy DJ, Smyth AE, et al. Magnetic resonance enterography findings as predictors of clinical outcome following antitumor necrosis factor treatment in small bowel Crohn's disease. Eur J Gastroenterol Hepatol. 2015;27(8):956-62.
Eder P, Katulska K, Krela-Kaźmierczak I, et al. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity. Abdom Imaging. 2015;40(7):2210-8.
Eder P, Michalak M, Katulska K, et al. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies. Sci Rep. 2015;5:10223.
MacIsaac KD, Baumgartner R, Kang J, et al. Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients. PLoS One. 2014;9(12):e113937.
Soliman E, El-Tantawi G, Matrawy K, Aldawoudy A, Naguib A. Local infliximab injection of sacroiliac joints in non-radiographic axial spondyloarthritis: Impact on clinical and magnetic resonance imaging parameters of disease activity. Mod Rheumatol. 2015;25(3):421-6.
Yonenaga T, Saeki H, Nakagawa H, et al. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions. J Dermatol. 2015;42(1):49-55.
Sakuraba H, Ishiguro Y, Hasui K, Hiraga H, Fukuda S, Shibutani K, Takai Y. Prediction of maintained mucosal healing in patients with Crohn's disease under treatment with infliximab using diffusion-weighted magnetic resonance imaging. Digestion. 2014;89(1):49-54.
Tielbeek JA, Löwenberg M, Bipat S, et al. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn's disease. Inflamm Bowel Dis. 2013;19(9):1943-50.
Van Assche G, Herrmann KA, Louis E, et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohns Colitis. 2013;7(12):950-7.
Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas. Inflamm Bowel Dis. 2012;18(10):1825-34.
Savoye-Collet C, Savoye G, Koning E, Dacher JN, Lerebours E. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis. 2011;17(8):1751-8.
Gligorijević V, Spasić N, Bojić D, et al. The role of pelvic MRI in assesment of combined surgical and infliximab treatment for perianal Crohn's disease. Acta Chir Iugosl. 2010;57(3):89-95.
Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol. 2011;9(2):130-6.
Rudwaleit M. Effects of low-dose infliximab on spinal inflammation on magnetic resonance imaging in ankylosing spondylitis. J Rheumatol. 2010;37(8):1553-5.
Horikoshi M, Suzuki T, Sugihara M, et al. Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis. Mod Rheumatol. 2010;20(6):556-60.
Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol. 2010;37(8):1728-34.
Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol. 2009;104(12):2973-86.
Fonseca JE, Canhão H, Tavares NJ, Cruz M, Branco J, Queiroz MV. Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 year. Clin Rheumatol. 2009;28(10):1213-6.
Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946-54.
Bonel HM, Boller C, Saar B, Tanner S, Srivastav S, Villiger PM. Short-term changes in magnetic resonance imaging and disease activity in response to infliximab. Ann Rheum Dis. 2010;69(1):120-5.
Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, Tam LS. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford). 2008;47(9):1358-63.
Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56(12):3919-27.
Toth C, Martin L, Morrish W, Coutts S, Parney I. Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurol Scand. 2007;116(4):259-62.
Gaylis NB, Needell SD, Rudensky D. Comparison of in-office magnetic resonance imaging versus conventional radiography in detecting changes in erosions after one year of infliximab therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2007;17(4):273-8.
Treves R, Dufauret-Lombard C, Vergne-Salle P, et al. Contribution of sacroiliac magnetic resonance imaging (MRI) to the evaluation of infliximab efficacy in spondyloarthropathy (a prospective study of 34 patients). Bull Acad Natl Med. 2006;190(4-5):995-1003.
Marzo-Ortega H, McGonagle D, Rhodes LA, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis. 2007;66(6):778-81.
Tam LS, Griffith JF, Yu AB, Li TK, Li EK. Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation. Clin Rheumatol. 2007;26(6):941-6.
Braun J, Landewé R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54(5):1646-52.
Argyropoulou MI, Glatzouni A, Voulgari PV, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with infliximab. Joint Bone Spine. 2005;72(6):557-61.
Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford). 2005;44(12):1525-30.
Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27-35.
Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003;48(4):1126-36.
Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98(2):332-9.
Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2003;17(3):387-93.
Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002;47(5):506-12.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
